Search

Your search keyword '"Golan, Y."' showing total 385 results
Start Over Author "Golan, Y."
385 results on '"Golan, Y."'

4. High-quality GaN on intentionally roughened c-sapphire

Author

Golan, Y, Fini, P, Dahan, D, Wu, F, Zamir, S, Salzman, J, and Speck, J S

Abstract

GaN films were grown using metal-organic chemical vapor deposition (MOCVD) on intentionally roughened c-sapphire in order to study the effect of the substrate roughness. Controlled substrate damage was achieved by exposing the substrate surfaces to controlled amounts of trimethylgallium followed by exposure to hydrogen at elevated temperature. The bulk film quality was studied by high-resolution X-ray diffraction and the surface topography was examined by atomic force microscopy. It was observed that mild substrate roughness (surface pit depth up to 30 nm) does not have a significant effect on the bulk film quality nor the GaN surface topography, and that recovery of the surface roughness is observed in very early stages of film growth. Cross sectional transmission electron microscopy confirmed that MOCVD GaN grown on inclined sidewalls etched in c-sapphire maintained the {0001}(sapphire) parallel to {0001}(GaN) epitaxial relationship despite the substrate miscut of ca. 15degrees with respect to the c-axis.

Published
2003

12. COVID-19 mRNA vaccine is not detected in human milk

Author

Stephanie L. Gaw, Nadav Ahituv, Golan Y, Clara Lin, Arianna G. Cassidy, Valerie J. Flaherman, and Mary Prahl

Subjects
Clinical trial, Emergency Use Authorization, Messenger RNA, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Physiology, Medicine, business, Human breast milk
Abstract

Several countries have recently approved the use of mRNA vaccines against COVID-19 under an emergency use authorization. However, no pregnant or lactating individuals were included in the Phase 3 clinical trials of these vaccines despite belonging to a group at high risk for severe complications of COVID-19 infection. We show here that the mRNA from anti-COVID BNT162b2 (Pfizer) and mRNA-1273 (Moderna) vaccines is not detected in human breast milk samples collected 4-48 hours post-vaccine. These results strengthen the recommendation of ABM and WHO that lactating individuals who receive the anti-COVID-19 mRNA-based vaccine should continue to breastfeed their infants uninterrupted.

Published
2021
Full Text
View/download PDF

22. Wild Visionary : Maurice Sendak in Queer Jewish Context

Author

Golan Y. Moskowitz and Golan Y. Moskowitz

Subjects
Authors, American--20th century--Biography, Illustrators--United States--Biography, Children's stories, American--Authorship, Jewish gay men--United States--Biography
Abstract

Wild Visionary reconsiders Maurice Sendak's life and work in the context of his experience as a Jewish gay man. Maurice (Moishe) Bernard Sendak (1928–2012) was a fierce, romantic, and shockingly funny truth seeker who intervened in modern literature and culture. Raising the stakes of children's books, Sendak painted childhood with the dark realism and wild imagination of his own sensitive'inner child,'drawing on the queer and Yiddish sensibilities that shaped his singular voice. Interweaving literary biography and cultural history, Golan Y. Moskowitz follows Sendak from his parents'Brooklyn home to spaces of creative growth and artistic vision—from neighborhood movie palaces to Hell's Kitchen, Greenwich Village, Fire Island, and the Connecticut country home he shared with Eugene Glynn, his partner of more than fifty years. Further, he analyzes Sendak's investment in the figure of the endangered child in symbolic relation to collective touchstones that impacted the artist's perspective—the Great Depression, the Holocaust, and the AIDS crisis. Through a deep exploration of Sendak's picture books, interviews, and previously unstudied personal correspondence, Wild Visionary offers a sensitive portrait of the most beloved and enchanting picture-book artist of our time.

Published
2021

30. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

Author

Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., Jenkin, G., Jensen, W., Kim, Y. -S., Yoshida, J., Gabryelski, L., Pedley, A., Eves, K., Tipping, R., Guris, D., Kartsonis, N., Playford G, Dorr M. -B., Mcgechie, D, Iredell, J, Allworth, A, Cheng, A, Choi, Nj, Thalhammer, F, Maieron, A, Wenisch, C, Meyer, B, Jacobs, F, Delmee, M, Peetermans, W, Giot, Jb, Munhoz, Al, Kallas, Eg, Ladeira, Jp, Bernstein, Cn, Grimard, D, Mcgeer, A, Poirier, A, Valiquette, L, Miller, M, Oughton, M, Trottier, S, Dolce, P, Smyth, D, Gambra, P, Palma, S, Rojas, L, Northland, R, Arellano, Mc, Perez, J, Barreto, Mf, Gomez, Jm, Ramirez, I, Correa, A, Onate, J, Rohacova, H, Stastnik, M, Zjevikova, A, Blazek, J, Kumpel, P, Petersen, Am, Gluud, Ll, Staugaard, Hm, Tvede, M, Glerup, H, Madsen, Sm, Helms, M, Naumann, R, Karthaus, M, Reinshagen, M, Raz, R, Giladi, M, Chowers, M, Bishara, J, Quirino, T, Castelli, F, Bassetti, M, Rizzardini, G, Vismara, E, Puoti, M, Viale, P, Menichetti, F, Cauda, R, Bonfanti, P, Franzetti, F, Gori, A, Minoli, L, Noriega, Er, Mills, Gd, Ritchie, S, Burns, A, Pithie, A, dos Santos RM, Aldomiro, F, Fernando, Pb, Rola, J, Reis, E, Van Zyl JH, Aboo, N, Richards, G, Hernandez, Mj, de Medrano VA, Prunonosa, Lm, Gonzalez, Jl, Reinoso, Jc, Martinez, Ar, Cisneros, Jd, Banos, Jr, Sheridan, R, Minton, J, Williams, J, Stanley, P, Guleri, A, Llewelyn, M, Todd, N, Barlow, G, Bacon, Ae, Baird, Im, Baxter, R, Zenilman, Jm, Beshay, M, Betts, Rf, Brettholz, Em, Buitrago, Mi, Carlson, Rw, Cook, Pp, Dupont, Hl, Foley, C, Freilich, B, Giron, Ja, Golan, Y, Green, S, Hall, Mc, Johnson, Dj, Jones, Rk, Graham, Dr, Kazimir, M, Keating, M, Brumble, Lm, Kumar, Pn, Liappis, Ap, Libke, R, Mehra, Pk, Overcash, Sj, Mullane, Km, Nguyen, Mh, Patel, Mc, Powers, Ck, Pullman, J, Keegan, J, Nepal, S, English, G, Ricci, Rl, Risi, Gf, Rodriguez, M, Schmitt, Cm, Sims, Md, Kamepalli, R, Tural, A, Vazquez, Ja, Alangaden, Gj, Weavind, Lm, Young, Ma, Chen, St, Liu, E, Nguyen, Hh, Alfonso, Tb, Muse, Dd, Orenstein, R, Yacyshyn, B, Gebhard, Re, Dinges, W, Bolton, M, Rubin, M, Kuemmerle, Jf, Limaye, Ap, Friedenberg, Ka, Hiemenz, Jw, Quadri, A, Martinez, Jv, Barcan, La, Cordova, E, Mykietiuk, A, Losso, M, Fedorak, Rn, Steiner, T, Gerson, M, Weiss, K, Dlouhy, P, Vitous, A, Benes, J, Husa, P, Knizek, P, Anttila, Vj, Broas, M, Camou, F, Postil, D, Launay, O, Corroyer-Simovic, B, Meynard, Jl, Schneider, S, Molina, Jm, Neau, D, Zalcman, G, Boutoille, D, Ostermann, H, Heinz, W, Reuter, S, Oren, I, Schiff, E, Umemoto, T, Masubuchi, T, Mukawa, K, Yasuda, K, Imokawa, S, Fukuda, K, Ohta, H, Harada, N, Fujii, S, Tamaki, S, Yasui, S, Furukawa, K, Takahashi, M, Uraoka, T, Watanabe, M, Ikehara, Y, Kodaira, M, Komatsu, H, Higashi, K, Taguchi, F, Ura, N, Serizawa, Y, Fukuchi, T, Ashikawa, T, Shabana, M, Okubo, M, Matsumoto, M, Kurihara, A, Miyasaka, E, Shimizu, M, Tominaga, H, Kubota, T, Kashiwazaki, M, Masuda, Y, Terasaki, S, Okafuji, H, Mieno, H, Urabe, T, Okamoto, E, Kajimura, M, Yamagishi, Y, Rydzewska, G, Mach, T, Ciechanowski, K, Podlasin, R, Tomasiewicz, K, Janczewska-Kazek, E, Czarnobilski, K, Halota, W, Gryglewska, B, Plesniak, R, Dabrowiecki, P, Lipowski, D, Simanenkov, V, Shcheglova, L, Uspenskiy, Y, Cheganov, A, Han, Ds, Kim, Js, Hong, Sp, Kim, Ti, Jang, Bi, Byeon, Js, Kim, E, Kim, Mj, Lee, J, Pai, H, Cheong, Hj, Lee, S, Loyarte, Ja, Gonzalez, Jc, Santiago, Eb, Lopez, Jr, Baranda, Jm, Viladomiu, As, Calbo, E, Lannergard, A, Falt, J, Gardlund, B, Andersson, Lm, Fraenkel, Cj, Rombo, L, Widmer, A, Chen, Yc, Sheng, Wh, Wang, Fd, Wang, Nc, Lee, Ch, Chen, Yh, Chuang, Yc, Unal, S, Ozaras, R, Esen, S, Ural, O, Ayaz, C, Sakarya, S, Celebi, A, Mistik, R, Bedimo, R, Bressler, A, Mckinley, Mj, Quirk, D, Talansky, Al, Agronin, Me, Akhrass, Fa, Ali, M, Alrabaa, Sf, Assi, Ma, Calfee, Dp, Carson, P, Mariani, Pg, Guerrero, D, Dubberke, Er, Hardi, R, Hazan-Steinberg, S, Itani, Km, Jauregui-Peredo, El, Kasabji, A, Hameed, M, Murillo, A, Odio, Aj, Shah, P, Braun, Ti, Slim, J, Sloan, L, Srinivasan, S, Tan, Mj, Clough, La, Herr, D, Miller, Lg, Dorfmeister, J, Khan, O, and Melik-Abrahamian, F.

Subjects
0301 basic medicine, Male, Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Antibodies, Monoclonal, Antibodies, Neutralizing, Clostridium Infections, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Infusions, Intravenous, Intention to Treat Analysis, Kaplan-Meier Estimate, Middle Aged, Secondary Prevention, Young Adult, Clostridium difficile, Clinical Trial, Phase III, Antibiotics, 0302 clinical medicine, Monoclonal, 80 and over, 030212 general & internal medicine, Medicine (all), Neutralizing, education.field_of_study, Research Support, Non-U.S. Gov't, General Medicine, Multicenter Study, Randomized Controlled Trial, Combination, Broadly Neutralizing Antibodies, Intravenous, medicine.medical_specialty, Infusions, medicine.drug_class, 030106 microbiology, Population, Placebo, Antibodies, 03 medical and health sciences, Pharmacotherapy, Drug Therapy, Internal medicine, Journal Article, medicine, education, Intention-to-treat analysis, Clostridioides difficile, business.industry, Interim analysis, Surgery, Bezlotoxumab, business
Abstract

BACKGROUND: Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy. Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, respectively.METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials, MODIFY I and MODIFY II, involving 2655 adults receiving oral standard-of-care antibiotics for primary or recurrent C. difficile infection. Participants received an infusion of bezlotoxumab (10 mg per kilogram of body weight), actoxumab plus bezlotoxumab (10 mg per kilogram each), or placebo; actoxumab alone (10 mg per kilogram) was given in MODIFY I but discontinued after a planned interim analysis. The primary end point was recurrent infection (new episode after initial clinical cure) within 12 weeks after infusion in the modified intention-to-treat population.RESULTS: In both trials, the rate of recurrent C. difficile infection was significantly lower with bezlotoxumab alone than with placebo (MODIFY I: 17% [67 of 386] vs. 28% [109 of 395]; adjusted difference, -10.1 percentage points; 95% confidence interval [CI], -15.9 to -4.3; PCONCLUSIONS: Among participants receiving antibiotic treatment for primary or recurrent C. difficile infection, bezlotoxumab was associated with a substantially lower rate of recurrent infection than placebo and had a safety profile similar to that of placebo. The addition of actoxumab did not improve efficacy. (Funded by Merck; MODIFY I and MODIFY II ClinicalTrials.gov numbers, NCT01241552 and NCT01513239 .).

Published
2017
Full Text
View/download PDF

33. Enhanced photoluminescence from GaN grown by lateral confined epitaxy.

Author

Zamir, S., Meyler, B., Salzman, J., Wu, F., and Golan, Y.

Subjects
PHOTOLUMINESCENCE, GALLIUM nitride, SILICON
Abstract

Lateral confined epitaxy (LCE) of GaN on Si substrates results in a reduction of thermal crack density with decreasing the lateral dimensions of the growth pattern. Below a critical size, crack-free GaN on Si is obtained. The intensity of band-to-band photoluminescence (PL) peak in LCE GaN is strongly enhanced with respect to uniformly grown GaN on Si. The present study rules out the effect of crack density, internal reflections (microcavity effects), as well as enhanced light extraction efficiency, and excitation or emission through preferred facets (shape effects) as the main factor in PL enhancement. It is shown that the reduction in threading dislocation density (TDD) along the edges of the LCE patterns improves the luminescence efficiency. The relative increase in high quality material (low TDD) with the reduction of LCE unit size is, thus, the main reason for the enhanced PL intensity. © 2002 American Institute of Physics. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

34. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials

Author

Mullane, KM, Cornely, OA, Crook, DW, Golan, Y, Louie, TJ, Miller, MA, Josephson, MA, and Gorbach, SL

Subjects
urologic and male genital diseases, female genital diseases and pregnancy complications
Abstract

BACKGROUND/AIMS: Patients with chronic kidney disease (CKD) have increased risk for Clostridium difficile infection (CDI) and for subsequent mortality. We determined the effect of CKD on response to treatment for CDI. METHODS: This is a post hoc analysis of two randomized controlled phase 3 trials that enrolled patients with CDI. Patients received either fidaxomicin 200 mg b.i.d. or vancomycin 125 mg q.i.d. for 10 days. Univariate and multivariate analyses compared end points by treatment received and CKD stage. RESULTS: At baseline, 27, 21, and 9% of the patients had stage 2 (60-89 ml/min/1.73 m(2)), stage 3 (30-59), and stage 4 or higher (

Published
2016

42. Abstracts of papers presented at the 6th conference of the weed science society of Israel: February 16-17, 1976 Rehovot, Israel

Author

Eshel, Y., Zimdahl, R. L., Schweizer, E. E., Rubin, B., Grinstein, A., Katan, J., Nir, I., Koller, D., Danin, A., Berg, Rivka, Umiel, N., Zilkha, S., Gressel, J., Horowitz, M., Herzlinger, G., Gizmawi, I., Koren, E., Shafir, N., Bucsbaum, H., Oren, Y., Bren, A., Stern, Y., Kleifeld, Y., Weiss, Y., Blumenfeld, T., Salomon, D., Sagi, Y., Magal, Z., Aronov, B., Sachs, Y., Zamir, G., Dahan, C., Marmelstein, M., Cohen, A., Bing, B., Lifshitz, N., Vanunu, E., Amir, J., Gur, Y., Shlevin, E., Alon, Y., Zuriel, S., Darr, S., Israeli, E., Shafrir, A., Beeri, M., Blass, I., Biran, Y., Gotlieb, A., Arenstein, Z., Golan, Y., Israeli, Y., Hameiri, Y., Alon, H., Riad, A., Sharaf, A., Sheinbaum, Y., Boshvitz, Y., Sofer, S., Karstadt, D., Nir, A., Brosh, S., Finkelstein, Y., Valis, G., Herman, M., Sando, Z., Diskin, I., Herzog, Z., Stern, A., and Golderman, K.

Published
1976
Full Text
View/download PDF

43. Abstracts of papers presented at a Symposium on Biological Control and Microbial Interactions Abstracts of papers presented at the French-Israeli Colloquium on Selection of Plants for Disease Resistance Abstracts of papers presented at the 3rd Meeting on Pheromone Research in Israel: March 14, 1982 Rehovt, Isral Mars 21–26, 1982 — Bordeaux, France May 4, 1982 Be’er Sheva, Israel

Author

Baker, R., Elad, Y., Sivan, A., Chet, I., Zilberstein, Y., Katan, J., Grinstein, A., Greenberger, A., Platt, M., Kenneth, R., Harman, G. E., Hüttermann, A., Haars, Annegret, Cwielong, P., Okon, Y., Bashan, Y., Cornuet, P., Bove, J. M., Renaudin, J., Mouches, C., Loebenstein, G., Gera, A., Doz, B., Delbos, R., Dunez, J., Lecoq, H., Pitrat, M., Cohen, S., Massonie, G., Maison, P., Dosba, Francoise, Doussinault, G., Jahier, J., Trottet, M., Eyal, Z., Rapilly, F., Auriau, Ph, Berville, A., Paillard, Michele, Netzer, D., Cohen, Y., Delon, R., Schiltz, P., Camporota, P., Artigues, M., Davet, P., Dubos, Bernadette, Jailloux, F., Bulit, J., Dunkelblum, E., Gothilf, S., Breuer, E., Lazarovici, P., Becker, D., Kimmel, Tamar, Shani, A., Klug, J. T., Ideses, Rut, Skorka, Jacqueline, Eliyahu, Rivka, Kehat, M., Yathom, Shoshana, Dahan, R., Chen, M., Tam, S., Szivos, Y., Bar-Zakkai, I., Malka, M., Peleg, B. A., Sternlicht, M., Rochel, A., Gurevitz, E., Halperin, J., Golan, Y., Hefetz, A., Jaacov, Rina Ben, Yom-Tov, Y., Kagan, R., Marder, J., and Ikan, R.

Published
1982
Full Text
View/download PDF

44. Abstracts of papers presented at

Author

Or, R., Fishler, G., Kehat, M., Chen, CH., Klein, Z., Dunkelblum, E., Gothilf, S., Muszkat, LEA, Melamed-madjar, VENEZIA, Yathom, SHOSHANA, Halperin, J., Mendel, Z., Bonneh, O., Saphir, NITZA, Golan, Y., Madar, Z., Moore, I., Snir, R., Harpaz, I., Mazor, MICHAL, Becker, D., Kimmel, T., Cyjon, R., Cosse, A., Wysoki, M., Hefetz, A., Graur, D., La-france, DALIA, Shani, A., Ravid, U., Ideses, RUT, Soroker, VICTORIA, Rafaeli, ADA, Nevo, E., Heth, G., Beiles, A., and Auffray, J. C.

Published
1987
Full Text
View/download PDF

47. Assessment of carrier multiplication in bulk PbS and PbSe

Author

Bonn, Mischa, Delerue, Christophe, Pijpers, J.J.H., Ulbricht, R., Tielrooijl, K.J., Osherov, A., Golan, Y., Allan, Guy, Max Planck Institute for Polymer Research, Max-Planck-Gesellschaft, Physique - IEMN (PHYSIQUE - IEMN), Institut d’Électronique, de Microélectronique et de Nanotechnologie - UMR 8520 (IEMN), Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA)-Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA), Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA), Department of Materials Engineering, Ilse Katz Institute for Nanoscience and Nanotechnology, Ben-Gurion University of the Negev (BGU), Centrale Lille-Institut supérieur de l'électronique et du numérique (ISEN)-Université de Valenciennes et du Hainaut-Cambrésis (UVHC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF), Université catholique de Lille (UCL)-Université catholique de Lille (UCL)-Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA), and Université catholique de Lille (UCL)-Université catholique de Lille (UCL)

Subjects
[PHYS.COND]Physics [physics]/Condensed Matter [cond-mat], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2011

48. Изменение оптических свойств и фазового состава имплантированных кремнием слоев SiO2 при легировании ионами фосфора, бора, азота и углерода

Author

Finstad, T. and Golan, Y.

Subjects
НАНОКРИСТАЛЛЫ КРЕМНИЯ,ДИОКСИД КРЕМНИЯ,ИОННАЯ ИМПЛАНТАЦИЯ,ИОННОЕ ЛЕГИРОВАНИЕ,ФОТОЛЮМИНЕСЦЕНЦИЯ,ФАЗОВЫЙ СОСТАВ
Abstract

Исследовано влияние ионно-лучевого легирования P, B, N и С на свойства термически выращенных слоев SiO2, имплантированных кремнием. Внедрение примесных атомов производилось как до, так и после отжигов при 1000 или 1100 °С, формирующих нанокристаллы Si. В некотором интервале доз ионное внедрение усиливает фотолюминесценцию SiO2, связанную с дефектами оксида. Внедрение фосфора при концентрациях до ~ 1 ат.% приводит к многократному усилению фотолюминесценции (700-750 нм) нанокристаллов Si, синтезированных при 1000 °С, и к ее ослаблению при больших концентрациях. Ослабление наблюдается также для синтезированных при 1100 °С нанокристаллов при легировании фосфором. Легирование бором, азотом и углеродом во всех случаях ослабляют эту полосу люминесценции. При легировании углеродом в матрице SiO2 формируются преципитаты карбида кремния, элементарного углерода и кремния, ответственные за излучение во всей видимой области спектра. Обсуждаются возможные причины полученных результатов., The influence of P, B, N and С ion-implantation doping on the properties of Si-implanted thermally grown SiO2 layers has been investigated. The impurity atoms were introduced either before or after annealing at 1000 °С or 1100 °С which forms Si nanocrystals. In a certain dose range, the ion implantation enhances the defect-related SiO2 photoluminescence. Introduction of phosphorus up to the concentration of ~ 1 at.% leads to a manifold improvement of 700-750 nm photoluminescence of Si nanocrystals synthesized at 1000 °С and to its quenching at higher concentrations. The quenching is also observed for the P-doped nanocrystals synthesized at 1100 °С. Doping with B, N and C reduces this luminescence band under all conditions. Silicon carbide, elemental carbon and silicon precipitates responsible for light emission in the whole visible region are formed in SiO2 matrix at carbon doping. Possible causes of the results obtained are discussed.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results